All News

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

This reduction in white matter has been well-documented, but the exact mechanism of action has been unknown until now, according to the study authors.

The study authors sought to evaluate whether the link between lifestyle and cognition varies by APOE genotype among the elderly.

The vaccine includes all 13 serotypes in the Prevnar 13 vaccine, as well as conjugates for 7 additional serotypes associated with high case-fatality rates, antibiotic resistance, and meningitis.

A study found that 14.4% of customers had sought information prior to visiting a community pharmacy.

Evinacumab-dgnb is the first FDA-approved treatment that binds to and blocks the function of angiopoietin-like 3, a protein that plays a key role in lipid metabolism.

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Patients with prostate cancer have to be approached differently depending on the state of their metastases.

Working in clinical research combines skills from both the retail and health system pharmacy spaces, as well as other, more unique skillsets, according to research pharmacist Brian Wortz, PharmD, of Cancer Treatment Centers of America, in an interview with Pharmacy Times.

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.

The use of IVIG in the treatment of recalcitrant pemphigus vulgaris and foliaceus and bullous pemphigoid is supported by 2 clinical trials.

It is important for health care providers to explain compliance to these regimens to patients, both from a clinical and cost perspective.

COVID-19 permanently changed how pharmacists recommend and sell nonprescription options.

Common precautions to prevent the spread of COVID-19 also decreased the rates of common respiratory illnesses in 2020 and early 2021.

Prescribers should be aware of new, second-generation antihistamines to manage hay fever and outbreaks of hives, according to a recent study.

Two studies in the 1990s identified gum bleeding as a biomarker for vitamin C levels, although this connection somehow disappeared in dental conversations around gum bleeding.

Research has shown that female adolescents and adolescents with darker skin are disproportionately affected by acne's psychological impacts.

Clinicians can play an important role in counseling patients about the 5 main OTC categories of laxatives to treat this gastrointestinal condition.

Pharmacy Times has been a constant source of up-to-date, practical information for the pharmacy community and has led the way in presenting valuable information on the OTC market—in print and via online venues.

Since 1997, Pharmacy Times has been calculating pharmacists’ OTC recommendations and publishing an annual survey.

The definition of oligometastatic disease has continued to be shrouded in uncertainty due to the varying assessment criteria that exist at present during trial analyses.

The development of precision medicine for pancreatic cancer has faced a number of challenges, including a lack of specific molecular-targeted drugs.

Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.

Jonathan Spicer, MD, medical director of the McGill University Health Center Thoracic Oncology Network, discusses what is still needed to be investigated in the future following the phase 3 trial assessing nivolumab plus platinum-doublet chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.